Clinical Trials · NCT03098797
A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome
- Phase
- Phase 2/Phase 3
- Recruitment status
- Completed
- Sponsor
- Stealth BioTherapeutics Inc.
- Enrollment
- 12
- Start date
- Jul 2017
- Locations
- 1 site, United States
- Primary endpoint
- Part 1: Distance Walked During the 6-Minute Walk Test (6MWT) by Visit